News &
Events
Corporate
Overview
Science &
Technology
R & D
Pipeline
Partnering
Investor
Relations
Media
Careers &
Jobs
| News in 2010 | |
 |
|
|
2010, July 22 |
|
|
2010, July 15 |
|
| 2010, July 5 Matter Group AG holds 3.4155% of share capital. |
|
| 2010, June 21 Disclosure of shareholding of Cytos Biotechnology Ltd pursuant to Art. 20 SESTA. |
|
| 2010, June 8 Cytos Biotechnology Ltd and Intercell AG close the sale of the platform technology. |
|
| 2010, May 21 Placebo-controlled phase II study shows CYT003-QbG10 is safe and efficacious for the treatment of allergic asthma. |
|
| 2010, May 6 Cytos Biotechnology sells platform technology for the identification of monoclonal antibodies to Intercell. |
|
| 2010, April 30 Harry Welten becomes new CFO at Cytos Biotechnology Ltd. |
|
| 2010, April 23 Constitution of the Board of Directors after the Shareholders’ Meeting 2010. |
|
| 2010, April 22 Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions. |
|
| 2010, April 22 Cytos' first quarter report. |
|
| 2010, March 22 Jakob Schlapbach (59) will resign as CFO of Cytos Biotechnology Ltd during the year 2010 and will be proposed to become a member of the board of directors. |
|
| 2010, March 4 Dr. Thomas Hecht succeeds Dr. François L'Eplattenier as chairman of the Board of Directors. |
|
| 2010, February 3 Cytos Biotechnology announces full year 2009 financial results and major developments in 2009. |
|
| News in 2009 | |
|
|
| 2009, November 10 Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb. |
|
| 2009, November 3 Disclosure of shareholding of Vontobel Fonds Services AG pursuant to Art. 20 SESTA |
|
| 2009, October 22 Cytos' third quarter report. |
|
| 2009, October 15 Interim analysis of an ongoing phase II study with nicotine vaccine shows primary endpoint not achieved. |
|
| 2009, July 31 CYT003-QbG10 monotherapy for the treatment of allergic rhinoconjunctivitis is safe and efficacious in phase IIb study. |
|
| 2009, July 30 Stichting Pensioenfonds ABP has fallen below the notifiable thresholds. |
|
| 2009, July 23 Cytos' second quarter report. |
|
| 2009, June 24 Cytos Biotechnology reports biochemical findings from phase IIa study with hypertension vaccine CYT006-AngQb. |
|
| 2009, June 11 Cytos Biotechnology initiates combined phase I/IIa study with a novel anti-interleukin-1 beta vaccine in patients with type II diabetes mellitus. |
|
| 2009, June 9 Disclosure of shareholding of Cytos Biotechnology Ltd pursuant to Art. 20 SESTA |
|
| 2009, May 13 GLS LP Investment V Ltd has fallen below the notifiable thresholds. |
|
| 2009, May 7 Information relating to the VLP influenza vaccine. |
|
| 2009, April 23 Annual Shareholder's Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions. |
|
| 2009, April 22 Cytos' first quarter report. |
|
| 2009, April 21 Cytos Biotechnology initiates phase IIa study with CYT003-QbG10 monotherapy in patients with allergic asthma bronchiale. |
|
| 2009, March 17 Cytos Biotechnology announces alignment of resources following setback in the development of its hypertension vaccine CYT006-AngQb. |
|
| 2009, March 4 InCentive Group holds 3.26% of share capital. |
|
| 2009, February 24 Stichting Pensioenfonds ABP holds 3.01% of share capital. |
|
| 2009, February 11 Cytos Biotechnology announces full year 2008 financial results and annual highlights. |
|
|
2009, January 13
Cytos Biotechnology presents analysis of patient diaries including six month follow-up data from phase II study with CYT003-QbG10 monotherapy for the treatment of allergic diseases. |
|
| 2009, January 5 Pfizer executes commercial license agreements for novel human vaccines based on Cytos Biotechnology's Immunodrug™ technology. |
|
| News in 2008 | |
|
|
| 2008, December 24 Vontobel Fonds Services AG holds 5.64% of share capital. |
|
| 2008, December 9 Cytos Biotechnology starts phase IIb clinical study with CYT003-QbG10 monotheraphy for the treatment of allergic diseases. |
|
|
2008, October 23
Cytos' third quarter report. - including long-term follow-up for the hypertension vaccine CYT006-AngQb. |
|
| 2008, October 17 FIL Limited has fallen below the notifiable thresholds. |
|
| 2008, August 15 Cytos Biotechnology and Pfizer enter into a research, option and license agreement for certain novel vaccines for a defined number of human diseases. |
|
|
2008, July 24
Cytos' second quarter report. - including an update on the two collaborative programs with Novartis in Alzheimer's disease and nicotine addiction. |
|
| 2008, July 10 CYT003-QbG10 monotherapy for the treatment of allergic diseases is safe and efficacious in placebo-controlled phase II study. |
|
| 2008, May 15 HBM BioVentures Ltd. has fallen below the notifiable thresholds. |
|
| 2008, April 24 Cytos Biotechnology's Annual Shareholders' Meeting 2008: Shareholders approve all resolutions. |
|
| 2008, April 24 Cytos' first quarter report. - including initiation of two phase II studies with CYT006-AngQb in hypertension and a phase IIa study with CYT004-MelQbG10 in malignant melanoma. |
|
| 2008, March 27 Deutsche Bank Aktiengesellschaft has fallen below the notifiable thresholds. |
|
| 2008, March 27 HBM BioVentures Ltd. holds 4.06% of share capital. |
|
| 2008, March 10 InCentive Group holds 6.51% purchase positions and 1.90% sale positions of share capital. |
|
| 2008, March 7 THE LANCET publishes phase IIa results for the hypertension vaccine CYT006-AngQb. |
|
| 2008, February 22 Vontobel Fonds Services AG holds 3.54% of share capital. |
|
| 2008, February 18 Deutsche Bank Aktiengesellschaft holds 2.980% purchase positions and 7.946% sale positions of share capital. |
|
| 2008, February 14 Cytos Biotechnology Announces Full Year 2007 Financial Results and Annual Highlights. |
|
| 2008, February 5 Deutsche Bank Aktiengesellschaft holds 3.407% purchase positions and 8.092% sale positions of share capital. |
|
| 2008, January 24 GLS LP Investment V Ltd holds 4.38% of share capital. |
|
| 2008, January 22 Disclosure of shareholding pursuant to Art. 20 SESTA by Cytos Biotechnology Ltd. |
|
| 2008, January 8 Deutsche Bank Aktiengesellschaft holds 4.102% purchase positions and 7.512% sale positions of share capital. |
For News Release Archive
as of the year 2000 click here